Back

Hemodynamic changes with pulmonary arterial hypertension targeted therapies: a meta-analysis of 3898 treatment-naive patients

27 August 2023 (08:48 - 09:06)
Organised by: Logo
Congress Presentation Part of: Molecular approaches to the treatment of pulmonary hypertension Pulmonary Hypertension ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Mr Ioannis Farmakis

Ludwig Maximilians University, Munich (Germany)

4 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on molecular approaches to the treatment of pulmonary hypertension
Doctor P. Thistlethwaite (La Jolla, US)
Slides Video
Presentation thumbnail
Development of KER-012, a modified ActRIIB ligand trap, for the treatment of pulmonary arterial hypertension
Doctor S. Cooper (Lexington, US)
Abstract Slides Video
Presentation thumbnail
Effects of inhaled seralutinib on right ventricular-pulmonary arterial (RV-PA) coupling and right heart function in pulmonary arterial hypertension (PAH)
Doctor K. Tello (Giessen, DE)
Abstract Slides Video
Presentation thumbnail
The effects of empagliflozin on right ventricular adaptation to pressure overload
Ms J. Axelsen (Aarhus, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Molecular approaches to the treatment of pulmonary hypertension
Video

The Event

Event poster

ESC Congress 2023

27 August 2023 08:48 CET
You may be interested in
thumbnail
Congress Presentation
Hemodynamic effects of add-on therapies in pulmonary arterial hypertension: an additive component network meta-analysis.
thumbnail
Congress Session
Molecular approaches to the treatment of pulmonary hypertension
thumbnail
Congress Presentation
When the right heart fails because of rising right ventricular afterload: aggressive afterload lowering with upfront triple therapy including parenteral prostacyclin

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources